Chemotherapy-Induced Dopaminergic Dysfunction (CIDD): A Synthesized Neurobiological Framework for Motivational and Cognitive Deficits in Cancer Survivorship

Background A significant proportion of cancer survivors completing active treatment experience persistent motivational flatness, cognitive slowing, and anhedonia that extends well beyond the acute treatment period and resists resolution through rest or standard antidepressant therapy. Despite affecting an estimated 30 to 60 percent of survivors, this syndrome remains largely absent from standard survivorship care plans and patient education materials. Survivors frequently attribute their symptoms to personal failure, laziness, or treatment-refractory depression, when the underlying cause is measurable neurobiological disruption of the brain's primary reward and motivation circuitry. The colloquial term chemobrain, while widely recognized, fails to capture the motivational and reward-processing component that renders this syndrome neurobiologically distinct from general cancer-related cognitive impairment and primary major depressive disorder. Purpose This paper proposes and describes Chemotherapy-Induced Dopaminergic Dysfunction (CIDD) as a clinically actionable neurobiological framework synthesizing peer-reviewed literature on chemotherapy-induced cognitive impairment, dopaminergic pathway disruption, NMDA receptor dysfunction, neuroinflammation, and HPA axis dysregulation. The framework is intended to facilitate more targeted clinical evaluation and treatment discussions for survivors presenting with motivational and cognitive deficits following cancer treatment, and to address a critical gap in survivorship care education for both patients and providers. Methods This paper presents a synthesized clinical framework developed through systematic review of peer-reviewed literature across oncology, neuroscience, neuropsychology, and survivorship medicine. Evidence was drawn from published research on chemotherapy-induced cognitive impairment, dopaminergic neurotoxicity, NMDA receptor disruption, neuroinflammatory mechanisms, immune checkpoint inhibitor-related neurological adverse events, and pharmacological interventions across cross-diagnostic populations including traumatic brain injury, multiple sclerosis, post-COVID fatigue syndrome, and oncology. The framework additionally integrates emerging literature on Sensory Processing Sensitivity as a neurobiological vulnerability factor in survivorship populations. Results The CIDD framework identifies four primary neurobiological mechanisms underlying post-chemotherapy motivational and cognitive deficits: mesolimbic dopamine pathway disruption, NMDA receptor dysfunction, neuroinflammatory cytokine suppression of dopaminergic signaling, and HPA axis dysregulation. These mechanisms are neurobiologically distinct from primary major depressive disorder and respond preferentially to dopaminergic and noradrenergic agents rather than serotonergic antidepressants alone. Amantadine is identified as a preferred first-line pharmacological agent. Methylphenidate, bupropion, and modafinil are described as additional evidence-supported options. Highly Sensitive Persons are identified as a potentially underrecognized vulnerable population within survivorship due to deeper neural processing and heightened stress reactivity. Conclusions CIDD represents a clinically significant and underrecognized syndrome affecting a substantial proportion of cancer survivors. Integration of the CIDD framework into standard survivorship care plans, provider education curricula, and patient advocacy resources has the potential to meaningfully improve quality of life and clinical outcomes for survivors currently underserved by existing diagnostic and treatment paradigms. Prospective clinical trials validating the CIDD framework as a formal diagnostic category are warranted.